Latest Breaking News On - Progress poster presentation - Page 1 : comparemela.com

First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two.

United statesMichael baileyUniversity of florida health cancer centerPharma united kingdomDrug administrationEuropean unionPharmaceuticals incAmerican cancer societyClinical oncology gastrointestinalFlorida health cancer centerChief executive officerSafety data poster titleAdvanced hepatocellular carcinomaEfficacy resultsPreviously untreated patientsProgress poster presentation